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Background
Doxorubicin (DOX) is a widely used chemotherapy drug
that causes irreversible cardiomyopathy in a growing
number of patients. An early detection method for this
side effect could positively impact patient care. Previous
work validated a molecular MRI probe that linked
human Annexin V (ANX), a protein that binds strongly
to early apoptotic cells, to superparamagnetic iron oxide
(SPIO). T2 weighted (T2W) cardiac MRI of ANX-SPIO
was found to detect DOX-induced cardiac apoptosis in
mice. Alpha-1AR adrenergic stimulation with A61603
(A6) has been shown to prevent DOX-induced apoptosis
and cardiac dysfunction in mice.
Hypothesis
T2-weight (T2W) MRI of an ANX-SPIO molecular probe
will detect reductions in DOX-induced apoptosis follow-
ing cardioprotective A6 therapy.
Methods
FVB/n mice were administered DOX (25 mg/kg, intra-
peritoneally) plus a subcutaneous mini-osmotic pump
secreting saline or A6 (10 ng/kg/day). Fractional short-
ening was assessed by echocardiography at day 0 and day
6 (Siemens Acuson, Inc.). ANX-SPIO was injected by tail
vein 2 days after DOX, and animals were imaged by T2W
cardiac MRI 24 hours later (3 Tesla GE Signa Excite T2W
GRE sequence: GRE TR 100/TE 10-20 ms/FA 60/FOV 4/
matrix 256 × 256/ST 0.8 mm/NEX 6). Ejection fraction
was also analyzed by cardiac MRI (Ziosoft, Inc.). Hearts
were excised and assayed for Caspase activity (Promega,
Inc.) to determine apoptosis signaling.
Results
DOX+A6 mice had preserved fractional shortening (FS
%) after 1 week compared to DOX+VEH mice and
preliminary T2* decay in mice receiving ANX-SPIO
revealed reduced myocardial iron uptake in DOX+A6
vs DOX+VEH (see Figure 1 and Table 1). Preliminary
ejection fractions (EF) by cardiac MRI tended to be
higher in DOX+A6 mice compared to DOX+VEH.
Decreased uptake of ANX-SPIO into DOX+A6 myocar-
dium was associated with a blunted increase in Caspase
3/7 activation, indicating reduced cardiac apoptosis.
Conclusion
T2W MRI of ANX-SPIO can non-invasively detect
cardioprotection by an alpha-1A adrenergic receptor
agonist A6 at an early timepoint. MRI of ANX-SPIO
may be useful in monitoring apoptotic signaling during
therapy for other cardiac disease states.
Figure 1
Short-Axis MRI from mice treated with DOX+VEH
(top) or DOX+A6 (bottom) and then administered
ANX-SPIO by tail vein. Echo time (TE) of 10 ms (left) vs
15 ms (right) is shown. Note rapid T2* signal loss in DOX
+VEH hearts, indicating increased ANX-SPIO uptake.
Table 1: Echo, MRI, and Caspase Data
Group N FS % T2* Decay EF% Caspase
(fold of Control)
Control 3 66 ± 2 29 ± 3 ms 57 ± 8 1.0 ± 0.3
DOX+VEH 3 55 ± 3* 12 ± 2 ms* 27 ± 8* 2.4 ± 0.3*
DOX+A6 2 67 ± 2 22 ± 4 ms 47 ± 2 1.3 ± 0.2
*-p < 0.05 vs control
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